Format

Send to

Choose Destination
Int Med Case Rep J. 2018 Mar 21;11:59-64. doi: 10.2147/IMCRJ.S163612. eCollection 2018.

First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study.

Author information

1
US Stem Cell, Inc., Sunrise, FL, USA.
2
US Stem Cell Clinic, Sunrise, FL, USA.

Abstract

Background:

Stromal vascular fraction (SVF) is a mixture of adipose-derived stem cells/mesenchymal stem cells, endothelial/progenitors, pericytes, fibroblasts, and other cells obtained from fat tissue. A small sample of fat or adipose tissue can be obtained under local anesthesia using a cannula. After an enzymatic digestion and centrifugation, the adipocytes (fat cells) are removed to obtain an SVF. Here, we describe the rationale and, to our knowledge, the first clinical implementation of SVF intravenously in a patient with severe psoriasis.

Methods:

Adipose tissue (60 mL) was collected under local anesthesia via a mini-lipoaspirate procedure. The SVF was separated from the adipocytes via centrifugation after an enzymatic digestion. The cells were resuspended in normal saline and injected via bolus push intravenous. The subject was monitored over a period of 12 months for safety (adverse events), medication changes, and quality of life parameters.

Results:

The patient did not report any safety concerns and did not experience any severe adverse events. The patient demonstrated a significant decrease in symptoms with a noticeable difference in skin quality appearance. Psoriasis area and severity index score went from 50.4 at baseline to 0.3 at 1 month follow-up.

Conclusion:

Overall, the patient reported improved quality of life and willingness to continue treatments. This successful initial case study demonstrates that this may be a feasible treatment plan for patients suffering from psoriasis.

KEYWORDS:

adipose tissue; adipose-derived stromal/stem cells; autoimmune disease; cell therapy; mesenchymal stem cells; psoriasis; stem cells; stromal vascular fraction

Conflict of interest statement

Disclosure KC is an officer of US Stem Cell, Inc. US Stem Cell is a publicly trading company providing physician-based stem cell therapies to human and animal patients as well as a developer of autologous cell therapies. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center